It was known that PSA (prostate specific antigen) the main marker for PCa is able to bind protease inhibitors in serum and this binding can be used for discrimination between PCa and BPH on basis of the free to total PSA ratio. Here, KLK3 is linked to benign prostatic hyperplasia.